RLYB earnings analysis
What we found in RLYB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Rallybio Corporation reported a significant revenue decline in Q4 2026, with revenue dropping to $38,000, missing estimates by 71.5%. Management indicated substantial operating losses of $8.3 million and a net loss per diluted share of -1.97, reflecting ongoing financial challenges, including a impact from a $50 million fee related to a terminated merger agreement.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Miss
- Revenue of $38,000 fell short of estimates of $133,330 by 71.5%.
- Operating Loss
- Operating loss of $8.3 million, improved from a loss of $9.4 million in 2025.
- Termination Fee Received
- Received a $50 million termination fee from the canceled merger with Candid Therapeutics.
- Cash Position
- Cash, cash equivalents, and marketable securities totaled $46.8 million.
- Decreased R&D Expenses
- Research and development expenses decreased from $5.7 million in Q1 2025 to $2.9 million in Q1 2026.
- No Product Revenue
- Continues to operate without any product revenue.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Loss of Merger Agreement
- Termination of the merger with Candid Therapeutics resulted in a $50 million fee.
- Ongoing Financial Losses
- Net losses for the period were $8.3 million, indicating ongoing financial instability.
- Cash Flow Risks
- Net cash used in operating activities was $7.98 million, necessitating additional funding.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.97
- Gross margin
- 100%
- Operating margin
- -4035.5%
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-K · March 16, 2026
- Rallybio is a clinical-stage biotech focused on RLYB116 (a once-weekly, subcutaneous C5 inhibitor) and preclinical RLYB332. The company reported confirmatory Phase 1 results in 2025 (improved tolerability and complete,…
- 10-Q · November 6, 2025
- Rallybio reported Q3 2025 revenue of $212,000 and GAAP net income of $16.0 million (EPS $0.36), driven primarily by a $22.48 million gain on the sale of its joint venture. Core operating results remain weak: Q3…
- 10-Q · August 7, 2025
- Rallybio reported Q2 2025 collaboration revenue of $212,000 and a net loss of $(9,703) (per the condensed consolidated statements). Operating expenses fell materially year-over-year (R&D $6,074, G&A $4,195; amounts in…
- 10-Q · May 8, 2025
- Rallybio reported $212,000 of revenue for Q1 2025 (first collaboration/license revenue) and a net loss of $9,439 (loss per share $(0.21)), an improvement versus Q1 2024 net loss of $19,029 (loss per share $(0.47)).…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RLYB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever